Drug intelligence / Profile preview

SPX-306

Development stage: Preclinical
Lead developer: SPARX THERAPEUTICS
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Oral

Overview

SPX-306 is an orally administered bispecific therapeutic candidate being developed by SparX Biopharmaceutical for the treatment of inflammatory diseases. It is designed to simultaneously inhibit Interleukin-23 (IL-23) and Tumor Necrosis Factor-like Ligand 1A (TL1A), two key cytokines involved in the pathogenesis of autoimmune and inflammatory conditions, particularly within the gastrointestinal tract. The dual inhibition of IL-23 and TL1A is intended to provide superior clinical outcomes compared to targeting either pathway alone. SPX-306 is currently in IND-enabling studies and is being developed as part of a collaboration with a NewCo.

Targets

TL1A (TNF-like cytokine 1A)IL-23 (Interleukin-23)

Beyond the preview

Go deeper on SPX-306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPX-306.

Explore the full profile